Rein Therapeutics Postpones Annual Meeting Due to Low Shareholder Turnout

AG真人官方

AG真人官方

[8-K] Rein Therapeutics, Inc. Reports Material Event

FAQ

[8-K] Rein Therapeutics, Inc. Reports Material Event

FAQ

[8-K] Rein Therapeutics, Inc. Reports Material Event

FAQ

Why did RNTX adjourn its 2025 Annual Meeting?

When is RNTX's rescheduled 2025 Annual Meeting?

What is the record date for RNTX's 2025 Annual Meeting?

When did RNTX file its proxy statement for the 2025 Annual Meeting?

Who is the current CEO of RNTX?

Why did RNTX adjourn its 2025 Annual Meeting?

When is RNTX's rescheduled 2025 Annual Meeting?

What is the record date for RNTX's 2025 Annual Meeting?

When did RNTX file its proxy statement for the 2025 Annual Meeting?

Who is the current CEO of RNTX?

NASDAQ:RNTX

RNTX Rankings

RNTX Latest News

RNTX Latest SEC Filings

RNTX Stock Data

Why did RNTX adjourn its 2025 Annual Meeting?

When is RNTX's rescheduled 2025 Annual Meeting?

What is the record date for RNTX's 2025 Annual Meeting?

When did RNTX file its proxy statement for the 2025 Annual Meeting?

Who is the current CEO of RNTX?

NASDAQ:RNTX

RNTX Rankings

RNTX Latest News

RNTX Latest SEC Filings

RNTX Stock Data

Trending News

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Rein Therapeutics (NASDAQ: RNTX) announced the adjournment of its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025. The meeting has been rescheduled to July 23, 2025 due to failure to achieve a quorum.

Key details of the adjournment:

Original meeting date: June 24, 2025
New meeting date: July 23, 2025
Record date remains: May 5, 2025
Purpose: To allow additional time for stockholders to vote on proposals outlined in the proxy statement filed May 12, 2025

The Form 8-K was filed by President and CEO Brian Windsor, Ph.D. from the company's Austin, Texas headquarters. This development indicates potential challenges in securing sufficient shareholder participation for important corporate governance matters.

06/24/2025 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 24, 2025

Rein Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-38130

13-4196017

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


12407 N. Mopac Expy., Suite 250 #390
Austin, Texas				78758
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (737) 802-1989

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

RNTX

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On June 24, 2025, Rein Therapeutics, Inc. (the “Company”) announced that it adjourned the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on Tuesday, June 24, 2025, until Wednesday, July 23, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 12, 2025. The record date for the Annual Meeting continues to be the close of business on May 5, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source:

RNTX adjourned its 2025 Annual Meeting, originally scheduled for June 24, 2025, because a quorum was not achieved. The meeting has been rescheduled to July 23, 2025, to allow stockholders more time to vote on the proposals outlined in the Company's May 12, 2025 proxy statement.

RNTX's rescheduled 2025 Annual Meeting will take place on Wednesday, July 23, 2025. The record date remains unchanged at the close of business on May 5, 2025.

The record date for RNTX's 2025 Annual Meeting is the close of business on May 5, 2025. This date remains unchanged despite the meeting's adjournment.

RNTX filed its definitive proxy statement with the Securities and Exchange Commission on May 12, 2025, containing the proposals to be voted on at the Annual Meeting.

Brian Windsor, Ph.D. serves as the President and Chief Executive Officer of Rein Therapeutics, Inc., as evidenced by his signature on the June 24, 2025 8-K filing.

REIN THERAPEUTICS, INC.

Date: June 24, 2025

/s/ Brian Windsor

Brian Windsor, Ph.D.

President and Chief Executive Officer